ストックスクリーナーアプリを入手
2.34
2.18%
0.05
アフターアワーズ：
2.38
0.04
+1.71%
Lantern Pharma Inc (LTRN) 最新ニュース
Lantern Pharma (LTRN) Q2 2026 Earnings Call Transcript - AOL.com
Lantern Pharma Inc (LTRN) (Q2 2026) Earnings Call Highlights: AI - GuruFocus
Lantern Pharma Inc (LTRN) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Lantern Pharma Inc. 2026 Q2ResultsEarnings Call Presentation (NASDAQ:LTRN) 2026-08-17 - Seeking Alpha
Lantern Pharma (LTRN) Slides 2.26% as Biotech Stock Approaches Critical $2.46 SupportKey Reversal Day - vinanet.vn
Lantern Pharma (LTRN) Updates Trial Design Amid Cash Raise; Mark - GuruFocus
Lantern Pharma (LTRN) Edges Up 0.76% to $2.65: Rangebound Trading Between Support and ResistanceBull Pennant - vinanet.vn
LTRN News | LANTERN PHARMA INC (NASDAQ:LTRN) - ChartMill
Form 8K Lantern Pharma Inc For: 14 August By Investing.com - Investing.com Nigeria
LTRN: Static price chart | Lantern Pharma Inc. | US51654W1018 - marketscreener.com
Lantern Pharma Reports 46.2% Wider Q2 2026 Loss at -$0.57/Share - AlphaStreet
Lantern Pharma Releases Q2 2026 Financial Results - AlphaStreet
Lantern Pharma (LTRN) Advances AI-Driven Oncology Pipeline Amid Valuation Challenges - GuruFocus
Lantern Q2 2026 slides: operating loss drops 25%, LP-300 data strengthens - Investing.com Canada
Lantern Pharma Inc. Q2 2026 Earnings Call Summary - Yahoo Finance
Earnings call transcript: Lantern Pharma posts q2 2026 loss miss as stock slips - Investing.com Nigeria
LTRN: AI-driven clinical pipeline and Open-Medicine AI spin-out drive growth amid reduced expenses - TradingView
LTRN: Open-Medicine AI spinout and clinical advances drove a leaner Q2 with reduced operating loss - TradingView
Lantern Pharma Q2 2026 Earnings Call Transcript - MarketBeat
BRIEF-Lantern Pharma Reports Second Quarter 2026 Financial Results And Provides Business Update - Dailyhunt
Q2 2026 Lantern Pharma Inc Earnings Call Transcript - GuruFocus
Lantern Pharma Q2 EPS of $(0.57) misses estimate by 50% - scanx.trade
Lantern Pharma Reports Second Quarter 2026 Financial Results And Provides Business Update - TradingView
Lantern Pharma Inc reports results for the quarter ended June 30Earnings Summary - TradingView
Is Lantern Pharma Inc (LTRN) Facing Increased Losses After Q2 Ea - GuruFocus
Lantern Pharma Forms Open Medicine AI Subsidiary Business - tipranks.com
Lantern Pharma Q2 operating loss widens on warrant expenses tied to higher stock price - TradingView
Lantern Pharma Inc. Q2 2026: Net income $(7.07M), EPS $(0.57) — 10-Q Summary - TradingView
Lantern Pharma Reports $7.1 Million Q2 Net Loss as LP-184 Trial Clears - Quiver Quantitative
Lung cancer trial narrows focus after 8.9-month progression-free result - Stock Titan
Lantern Pharma (LTRN) Earnings Date and Reports 2026 $LTRN - MarketBeat
Why Did LTRN Stock Surge 18% In Pre-Market Today? - Stocktwits
Certain Common Stock of Lantern Pharma Inc. are subject to a Lock-Up Agreement Ending on 13-AUG-2026. - marketscreener.com
Lantern Pharma Inc expected to post a loss of 38 cents a shareEarnings Preview - TradingView
Lantern Pharma (LTRN.US) will release its earnings report before market open on August 14. - Moomoo
Empery Asset Management, LP Acquires 1.3 Million Shares of Lantern Pharma Inc (LTRN) - GuruFocus
Lantern Pharma to Report Second Quarter 2026 Operating & Financial Results on August 14th, 2026 at 9:00 a.m. ET - Business Wire
LTRN Price History for Lantern Pharma Stock - Barchart.com
LTRN Q2'26 Earnings: revenue estimate is 0 USD - TradingView
Lantern Pharma (LTRN): Empery Asset Management discloses 9.99% beneficial stake - Stock Titan
Lantern Pharma Spins Off Open-Medicine AI Platform - TipRanks
Lantern Pharma (Nasdaq: LTRN) Establishes Open-Medicine AI as a Separate Company to Commercialize and Expand Its Multi-Agent AI Co-Scientist Platform for the Transformation of Medicine - BioSpace
Lantern Pharma (LTRN) Establishes Open-Medicine AI to Expand Mul - GuruFocus
Lantern Pharma establishes Open-Medicine AI to commercialize multi-agent AI co-scientist platform - TradingView
Lantern Pharma spins out AI platform into Open-Medicine AI - Investing.com
Lantern Pharma spins out AI platform into Open-Medicine AI By Investing.com - Investing.com Canada
Lantern Pharma’s bladder cancer trial cleared by EMA - Investing.com Nigeria
Lantern Pharma (LTRN) Gains EMA Approval for Phase 1b/2 Trial in Bladder Cancer - GuruFocus
Two Tumor Markers Will Guide Lantern Pharma's Bladder Cancer Trial - Stock Titan
Lantern Pharma (LTRN) Slides 6.8% as Stock Tests Key Support at $2.47Wyckoff Upthrust - vinanet.vn
LTRN|Lantern Pharma Inc|Price:2.890|Chg%:+0.140 - TradingKey
Lantern Pharma Inc (LTRN) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Lantern Pharma Inc (LTRN) Valuation: PE, PB & Fair Value Analysis - TradingKey
Lantern Pharma Inc (LTRN) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Lantern Pharma Inc (LTRN) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
TradingKey - TradingKey
Lantern Pharma Inc. Revenue Breakdown – NASDAQ:LTRN - TradingView
LTRN|Lantern Pharma Inc|Price:2.750|Chg%:-0.120 - TradingKey
Lantern Pharma (LTRN) investor Thomas Satterfield discloses 7.6% stake and 975,000 shares - Stock Titan
Lantern Pharma Receives USPTO Notice of Allowance for Patent Covering Biomarker-Guided Treatment with LP-184 (Zirdafulven) in Multiple Solid Tumor Cancers - BioSpace
1.21%
1.07%
大文字化:
|
ボリューム (24 時間):